Fineline Cube

Follow:
14483 Articles
AbbVie's Elahere Receives EC Approval for FRα-Positive Ovarian Cancer Treatment
CompanyMedical Device

AbbVie’s Elahere Receives EC Approval for FRα-Positive Ovarian Cancer Treatment

Rona Therapeutics' RN0191 Showcases Positive Phase I Results at AHA Scientific Sessions
CompanyDrug

Rona Therapeutics’ RN0191 Showcases Positive Phase I Results at AHA Scientific Sessions

Eli Lilly's Tirzepatide Meets Primary Endpoints in Phase III SUMMIT Heart Failure Study
CompanyDrug

Eli Lilly’s Tirzepatide Meets Primary Endpoints in Phase III SUMMIT Heart Failure Study

Zai Lab Ltd Announces Secondary Public Offering Worth $230 Million
CompanyDeals

Zai Lab Ltd Announces Secondary Public Offering Worth $230 Million

AstraZeneca's Tagrisso Receives Positive CHMP Opinion for EGFR-Mutated NSCLC
CompanyDrug

AstraZeneca’s Tagrisso Receives Positive CHMP Opinion for EGFR-Mutated NSCLC

Everest Medicines' Nefecon Receives Full Approval from South Korea's MFDS for IgAN Treatment
CompanyDrug

Everest Medicines’ Nefecon Receives Full Approval from South Korea’s MFDS for IgAN Treatment

Eli Lilly's Muvalaplin Demonstrates Potent Lp(a) Reduction in Phase II Study
CompanyDrug

Eli Lilly’s Muvalaplin Demonstrates Potent Lp(a) Reduction in Phase II Study

Sunshine Guojian Pharmaceutical's SSGJ-608 Files for NMPA Approval in Plaque Psoriasis
CompanyDrug

Sunshine Guojian Pharmaceutical’s SSGJ-608 Files for NMPA Approval in Plaque Psoriasis

Huahui Health's Libevitug Earns FDA Breakthrough Designation for Chronic Hepatitis Delta Virus
CompanyDrug

Huahui Health’s Libevitug Earns FDA Breakthrough Designation for Chronic Hepatitis Delta Virus

Xeltis AG Enrolls First Patient in US Pivotal Trial for aXess with FDA BTD Status
CompanyMedical Device

Xeltis AG Enrolls First Patient in US Pivotal Trial for aXess with FDA BTD Status

Shanghai Leadingtac Pharmaceutical Secures $13.81 Million in Series A Financing
CompanyDeals

Shanghai Leadingtac Pharmaceutical Secures $13.81 Million in Series A Financing

Huadong Medicine's DR10624 Receives NMPA Approval for MAFLD and MASH Clinical Trials
CompanyDrug

Huadong Medicine’s DR10624 Receives NMPA Approval for MAFLD and MASH Clinical Trials